Home
Resources
Publications
New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate

New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate

Lars Edvinsson, Mattias Linde

Lancet. 2010 Aug 21;376(9741):645-55.

PMID: 20416945

Abstract:

Although the triptan drugs provide effective relief from migraine for many patients, a substantial number of affected individuals are unresponsive to these compounds, and such therapy can also lead to a range of adverse effects. Telcagepant represents a new class of antimigraine drug-the calcitonin gene-related peptide receptor blockers. This compound exerts its effects by blocking receptors for the calcitonin-gene-related peptide at several sites in the trigeminal and central nervous systems, resulting in pain relief. Telcagepant does not cause vasoconstriction, a major limitation in the use of triptans. Comparisons with triptans in clinical trials for acute treatment of migraine attacks revealed clinical effects similar to those of triptans but better than those of placebo. Telcagepant might provide hope for those who have a poor response to, or are unable to use, older drugs. In patients who need prophylaxis because of frequent attacks of migraine, topiramate is a first-line drug for migraine prevention in many countries; it is generally safe and reasonably well tolerated. Data suggest that topiramate could aid reversion of chronic migraine to episodic migraine.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP20880926	Topiramate Related Compound A		20880-92-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: